ROCHE HOLDING AG

ISIN: CH0012032113 WKN: 1203211 Asset Class: Stock



Company Profile

Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12. 2022 2021 2023 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity 33,816,000,000 **Current assets** 33.446.000.000 35.627.000.000 Common stock capital 107,000,000 107,000,000 160,000,000 **Fixed assets** 57,022,000,000 54,335,000,000 56,690,000,000 Equity capital of a company 33,263,000,000 32,015,000,000 28,345,000,000 5,376,000,000 4,991,000,000 6,850,000,000 Cash and cash equivalents **Accrued liabilities** 5 438 000 000 5 672 000 000 7 545 000 000 Other assets **Current liabilities** 24.824.000.000 27.239.000.000 38.416.000.000 Prepayments and accrued income Non-current liabilities 32,381,000,000 28,897,000,000 25,556,000,000 Different income Other liabilities 259,000,000 298,000,000 282,000,000 Total assets 90.468.000.000 90.468.000.000 88.151.000.000 92.317.000.000 88 151 000 000 92 317 000 000

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	103,605	103,613	100,920
Equity ratio	41.13%	40.88%	34.88%
Debt-equity ratio	143.12%	144.61%	186.69%

2023

12.20%

2022

17.08%

Tax Expense Rate

2021

14.16%

ROCHE HOLDING AG

ISIN: CH0012032113 WKN: 1203211 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	58,716,000,000	63,281,000,000	62,801,000,000
Net income	11,498,000,000	12,421,000,000	13,930,000,000
EBIT	15,796,498,600	17,950,422,400	18,759,333,400
Operating income before taxes	14,111,000,000	16,368,000,000	17,400,000,000
Cash Flow	15,493,000,000	17,890,000,000	20,569,000,000
Net interest income	-828,000,000	-608,000,000	-341,000,000
Research and development expenses	13,231,000,000	14,050,000,000	13,707,000,000
Income taxes	1,721,000,000	2,796,000,000	2,463,000,000
Result from investments in subsidaries, associates and other	-32,000,000	-41,000,000	-2,000,000
Revenues per employee	599,260	645,801	658,004

Board of Directors		

Members of Management Board		
Thomas Schinecker	Chairman of Managing Board	
Alan Hippe	Member of Executive Committee	
Aviv Regev	Member of Executive Committee	
Dr. Hans Clevers	Member of Executive Committee	
James H. Sabry	Member of Executive Committee	
Levi Garraway	Member of Executive Committee	
Barbara Schädler	Member of Executive Committee	
Claudia Böckstiegel	Member of Executive Committee	
Cristina A. Wilbur	Member of Executive Committee	
Matt Sause	Member of Executive Committee	
Silke Hörnstein	Member of Executive Committee	
Teresa Graham	Member of Executive Committee	